DIAN DIAGNOSTICS GROUP CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.1 CNY | -3.95% |
|
-1.54% | -40.78% |
| Sales 2024 * | 13.89B 1.92B | Sales 2025 * | 17.16B 2.37B | Capitalization | 8.73B 1.21B |
|---|---|---|---|---|---|
| Net income 2024 * | 613M 84.66M | Net income 2025 * | 1.17B 161M | EV / Sales 2024 * | 0.72 x |
| Net Debt 2024 * | 1.27B 176M | Net Debt 2025 * | 1.42B 197M | EV / Sales 2025 * | 0.59 x |
| P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
7.57
x | Employees | 10,843 |
| Yield 2024 * |
1.02% | Yield 2025 * |
1.44% | Free-Float | 34.91% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.95% | ||
| 1 week | -1.54% | ||
| Current month | -19.34% | ||
| 1 month | -19.34% | ||
| 3 months | -23.41% | ||
| 6 months | -37.11% | ||
| Current year | -40.78% |
1 week
13.73
14.73
1 month
13.7318.15
Current year
13.7323.88
1 year
13.7327.98
3 years
13.7341.68
5 years
13.7352.38
10 years
13.7386.97
| Managers | Title | Age | Since |
|---|---|---|---|
Hai Bin Chen
FOU | Founder | 55 | 95-12-31 |
De Kang Zhao
DFI | Director of Finance/CFO | 56 | 23-08-28 |
Bai Xìng Huang
BRD | Director/Board Member | 68 | 19-05-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Guo Qi Ding
BRD | Director/Board Member | 55 | 17-07-16 |
Hai Bin Chen
FOU | Founder | 55 | 95-12-31 |
Tang Jiang
BRD | Director/Board Member | 65 | 15-01-29 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.33% | 12 M€ | -16.71% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 14.1 | -3.95% | 21,970,120 |
| 24-04-29 | 14.68 | +3.89% | 24,507,710 |
| 24-04-26 | 14.13 | -0.77% | 19,943,200 |
| 24-04-25 | 14.24 | +0.64% | 12,072,360 |
| 24-04-24 | 14.15 | -1.74% | 12,499,240 |
End-of-day quote Shenzhen S.E., April 29, 2024
More quotes
Dean Diagnostic Technology Group Co., Ltd. is a company providing integrated solutions for medical diagnosis. The Company's main business involves inspection services, product services, health management, judicial expertise, contract research organization (CRO), cold chain logistics and other fields. The Company's business is mainly oriented to medical and health institutions at all levels, such as various general and specialized hospitals, community health service centers, township (town) health centers, physical examination centers, disease prevention and control centers, etc. The Company's products include Atomic Bomb in the field of liquid phase mass spectrometry, Hydrogen Bomb in the field of nucleic acid mass spectrometry, and Man-Made Satellite in the field of pathological diagnosis products and molecular diagnosis products, and others.
Calendar
2024-05-20
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
14.1
CNY
Average target price
27.31
CNY
Spread / Average Target
+93.69%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.78% | 1.21B | |
| -19.14% | 8.22B | |
| +45.10% | 3.73B | |
| -7.18% | 2.46B | |
| -38.71% | 2.46B | |
| -8.65% | 2.36B | |
| -13.72% | 1.78B | |
| -19.73% | 1.52B | |
| +8.32% | 1.12B | |
| -12.27% | 1.09B |
- Stock Market
- Equities
- 300244 Stock
